Drugs / Sanfetrinem Cilexetil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05388448 | Apr 2022 → Aug 2024 | pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sanfetrinem Cilexetil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05388448 ↗ |
| Known as | GV 118819X | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107073 ↗ |
| Modality | Small molecule | “Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.” PMID 40020440 ↗ Feb 2025 |
| Route | Oral | “All treatments will be administered orally (PO) on days 1-14.” NCT05388448 ↗ |